ASCO Breast Cancer Biomarkers GUIDELINES App
Issue link: https://eguideline.guidelinecentral.com/i/848809
Mammostrat Î If a patient has ER/PgR-positive, HER2-negative (node-positive or node- negative) breast cancer, the clinician should NOT use the five-protein assay (Mammostrat; Clarient, a GE Healthcare company, Aliso Viejo, CA) to guide decisions on adjuvant systemic therapy. (Moderate Recommendation; EB-I) Î If a patient has HER2-positive breast cancer or TN breast cancer, the clinician should NOT use the five-protein assay (Mammostrat) to guide decisions on adjuvant systemic therapy. (Strong Recommendation;IC-Ins) Immunohistochemistry 4 (IHC4) Î If a patient has ER/PgR-positive, HER2-negative (node-positive or node-negative) breast cancer, the clinician should NOT use immunohistochemistry 4 (IHC4) to guide decisions on adjuvant systemic chemotherapy. (Moderate Recommendation; EB-I) Î If a patient has HER2-positive breast cancer or TN breast cancer, the clinician should NOT use IHC4 to guide decisions on adjuvant systemic therapy. (Strong Recommendation;IC-Ins) Urokinase Plasminogen Activator and Plasminogen Activator Inhibi- tor Type 1 Î If a patient has ER/PgR-positive, HER2-negative (node-negative) breast cancer, the clinician may use urokinase plasminogen activator and plasminogen activator inhibitor type 1 to guide decisions on adjuvant systemic therapy. (Weak Recommendation; EB-H) Î If a patient has HER2-positive breast cancer or TN breast cancer, the clinician should NOT use urokinase plasminogen activator and plasminogen activator inhibitor type 1 to guide decisions on adjuvant systemic therapy. (Weak Recommendation; IC-Ins) Circulating Tumor Cells Î The clinician should NOT use circulating tumor cells to guide decisions on adjuvant systemic therapy. (Strong Recommendation; EB-I) Tumor-Infiltrating Lymphocytes Î If a patient has ER/PgR-positive, HER2-negative (node-positive or node- negative) breast cancer, the clinician should NOT use tumor infiltrating lymphocytes to guide decisions on adjuvant systemic therapy. (Strong Recommendation; IC-Ins) Î If a patient has HER2-positive breast cancer or TN breast cancer, the clinician should NOT use tumor-infiltrating lymphocytes to guide decisions on adjuvant systemic therapy. (Strong Recommendation; EB-I) Protein Encoded By The MKI67 Gene Î Protein encoded by the MKI67 gene labeling index by IHC should NOT be used to guide choice on adjuvant chemotherapy. (Moderate Recommendation; EB-I)